Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Mayo Clinic, Rochester, Minnesota Baylor College of Medicine, Houston, Texas Germany
University Medical Center of the Johannes Gutenberg-University Mainz, Mainz South Korea
Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do Seoul National University Hospital, Seoul